Table 1.
Demographic and clinical data of the training and test groups.
| PD patients | Older adults | |||
|---|---|---|---|---|
| Lab assessment | ||||
| Training cohort 1 | ||||
| N (females) | 3 (2) | 2 (1) | ||
| Age (years) | 72.3 (4.7) | 71.0 (2.8) | ||
| MDS-UPDRS III (0–132) | 26 (15) | 2 (2) | ||
| H&Y (0–5) | 2 (1) | 0 (0) | ||
| LED (mg) | 640 (353) | 0 (0) | ||
| Test cohort 1 | ||||
| N (females) | 11 (5) | 12 (4) | ||
| Age (years) | 74.7 (7.2) | 70.8 (3.0) | ||
| MDS-UPDRS III (0–132) | 39 (9) | 1 (2) | ||
| H&Y (0–5) | 3 (1) | 0 (0) | ||
| LED (mg) | 540 (298) | 0 (0) | ||
| Home-like assessment | ||||
| Training cohort 2 | ||||
| N (females) | 4 (2) | 2 (1) | ||
| Age (years) | 69.3 (3.6) | 63.0 (17.0) | ||
| MDS-UPDRS III (0–132) | 20 (8) | 1 (0) | ||
| H&Y (0–5) | 2 (1) | 0 (0) | ||
| LED (mg) | 683 (735) | 0 (0) | ||
| Test cohort 2 | ||||
| N (females) | 21 (11) | 12 (6) | ||
| Age (years) | 66.4 (9.0) | 58.4 (8.9) | ||
| MDS-UPDRS III (0–132) | 32 (12) | 2 (4) | ||
| H&Y (0–5) | 3 (1) | 0 (0) | ||
| LED (mg) | 841 (604) | 0 (0) | ||
Data are shown as mean ± SD, except gender.
H&Y, Hoehn and Yahr; LED, Levodopa equivalent dose; PD, Parkinson’s disease; MDS-UPDRS III, motor part of the revised Unified PD Rating scale.